Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A Multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group

Journal of Clinical Oncology

Volumn 29, Issue 26, 2011, Pages 3559-3566

  Fischer, Kirsten ^a   Cramer, Paula ^a   Busch, Raymonde ^b   Stilgenbauer, Stephan ^c   Bahlo, Jasmin ^a   Schweighofer, Carmen D ^a   Boẗtcher, Sebastian ^d   Staib, Peter ^e   Kiehl, Michael ^f   Eckart, Michael J ^g   Kranz, Gabriele ^a   Goede, Valentin ^a   Elter, Thomas ^a   Buḧler, Andreas ^c   Winkler, Dirk ^c   Kneba, Michael ^d   Doḧner, Hartmut ^c   Eichhorst, Barbara F ^a   Hallek, Michael ^a   Wendtner, Clemens Martin ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e Sankt Antonius Hospital   (Germany)

^f Klinikum Frankfurt/Oder   (Germany)

^g Internistische Schwerpunkt Praxis Naegelsbacherstrasse   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOLYSIS; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; REFRACTORY CHRONIC LYMPHATIC LEUKEMIA; SEPTICEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TRISOMY 12; TUMOR LYSIS SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; DRUG TOXICITY; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NITROGEN MUSTARD COMPOUNDS; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL ANALYSIS; VIDARABINE;

EID: 80053020928     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.8061     Document Type: Article

References (29)

1. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
2. Dreger P, Dohner H, Ritgen M, et al: Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 116:2438-2447, 2010
3. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007 (Pubitemid 47069536)
4. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006 (Pubitemid 43156283)
5. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-798, 2007 (Pubitemid 350002879)
6. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989 (Pubitemid 19187405)
7. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005 (Pubitemid 46211313)
8. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
9. Wierda W, O'Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005 (Pubitemid 46211312)
10. Robak T, Dmoszynska A, Solal-Celigny P, et al: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756-1765, 2010
11. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
12. Keating MJ, O'Brien S, Kontoyiannis D, et al: Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43:1755-1762, 2002 (Pubitemid 34874007)
13. Stilgenbauer S, Zenz T, Winkler D, et al: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27:3994-4001, 2009
14. Ozegowski W, Krebs D: W-[bis-(chlorethyl)-amino-benzimidazolyl-(2)]- propionic or butyric acids as potential cytostatic agents. J Prakt Chem 20:178-186, 1963
15. Ozegowski W, Krebs D: IMET 3393, gamma-(1-methyl-5-bis-(β- chloräthyl)-amino-benzimidazolyl(2)-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste. Zbl Pharm 110:1013-1019, 1971
16. Hartmann M, Zimmer C: Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 287:386-389, 1972
17. Cheson BD, Wendtner CM, Pieper A, et al: Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: Treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10:21-27, 2010
18. Knauf WU, Lissichkov T, Aldaoud A, et al: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384, 2009
19. Bergmann MA, Goebeler ME, Herold M, et al: Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica 90:1357-1364, 2005 (Pubitemid 41503651)
20. Chow KU, Sommerlad WD, Boehrer S, et al: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 87:33-43, 2002 (Pubitemid 34101111)
21. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005
22. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 114:405, 2009 (abstr)
23. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996 (Pubitemid 26189840)
24. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v3.0. http://ctep.info.nih.gov/ protocolDevelopment/electronic-applications/ctc.htm#ctc-30
25. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999 (Pubitemid 29430399)
26. Böttcher S, Stilgenbauer S, Busch R, et al: Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: A comparative analysis. Leukemia 23:2007-2017, 2009
27. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
28. Reck M, Haering B, Koschel G, et al: [Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine: A phase II study]. Pneumologie 52:570-573, 1998
29. Cheson BD, Kroll ML: Bendamustine induced neurotoxicity. Clin Adv Hematol Oncol 7:743-746, 2009